Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
ACS Chemical Neuroscience|August 28, 2024
Discovery of VU6007496: Challenges in the Development of an M<sub>1</sub> Positive Allosteric Modulator Backup CandidateJulie L Engers, Katrina A Bollinger, Rory A Capstick, et al.
ACS Chemical Neuroscience|March 25, 2025
Application of Deuterium in an M<sub>1</sub> Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422Julie L Engers, Jinming Li, Changho Han, et al.
ACS Chemical Neuroscience|January 26, 2026
Discovery of 7-(Pyridin-3-yl)thieno[3,2-<i>b</i>]pyridine-5-carboxamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Scott H Henderson, Anna E Ringuette, David L Whomble, et al.
ACS Medicinal Chemistry Letters|December 18, 2024
Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Elizabeth S Childress, Rory A Capstick, Katherine E Crocker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of Thieno[3,2-<i>b</i>]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Katherine E Crocker, Scott H Henderson, Rory A Capstick, et al.
ACS Chemical Neuroscience|January 25, 2026
Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust <i>In Vivo</i> EfficacyAlison R Gregro, Charlotte Park, Madeline F Long, et al.
ACS Chemical Neuroscience|December 11, 2024
Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical TrialsMichael S Poslunsey, Michael R Wood, Changho Han, et al.
Pageof 4